Product Name:
EphA4-pY602
Product Number:
ab-pk930
Target Full Name: Ephrin type-A receptor 4 protein-tyrosine kinase
Target Alias: EC 2.7.1.112; EC 2.7.10.1; EPH receptor A4; HEK8; Receptor protein-tyrosine kinase HEK8; SEK; TYRO1; Tyrosine-protein kinase receptor SEK
Product Type Specific: EphA4 protein kinase phosphosite-specific antibody
Antibody Code: PK930
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y602
Protein UniProt: P54764
Protein SigNET: EphA4
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human EphA4
Antibody Immunogen Sequence: C(βA)PFT(pY)EDP
Antibody Immunogen Description: Corresponds to amino acid residues P599 to P606. Y602 phosphorylation stimulates phosphotransferase activity. This is one of the major in vivo phosphorylation sites with ≥169 mass spectrometry reports recorded in PhosphoSitePlus. EphA4 is known to be phosphorylated at this site in vitro by EphA4.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human | Chimpanzee | Rhesus Macaque | Dog | Mouse | Platypus | Chicken | Frog
Antibody Cross Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Mouse | Platypus | Chicken | Frog.
Related Product 1: EphA1 Y599 phosphorylation antibody (Cat. No.: AB-PK928)
Related Product 2: EphA1 Y781 phosphorylation antibody (Cat. No.: AB-PK605)
Related Product 3: EphA2 Y588 phosphorylation antibody (Cat. No.: AB-PK606)
Related Product 4: EphA2 Y772 phosphorylation antibody (Cat. No.: AB-PK607)
Related Product 5: EphA3 Y779 phosphorylation antibody (Cat. No.: AB-PK608)
Related Product 6: EphA4 Y596 phosphorylation antibody (Cat. No.: AB-PK929)
Related Product 7: EphA4 Y779 phosphorylation antibody (Cat. No.: AB-PK931)
Related Product 8: EphB1 Y594 phosphorylation antibody (Cat. No.: AB-PK609)
Related Product 9: EphB2 expression antibody (Cat. No.: AB-NK267-1)
Related Product 10: EphB2 expression antibody (Cat. No.: AB-NK267-2)
Scientific Background: Eph4 is a receptor protein-tyrosine kinase in the Eph family that can be physiologically activated by both GPI-anchored ephrin-A and transmembrane ephrin-B ligands including EFNA1 and EFNB3. It Interacts with the src family kinase, p59-Fyn, through the major phosphorylation site at position Tyr-602. EphA4 is involved in development of the nervous system by controlling different steps of axonal guidance including the establishment of the corticospinal projections. It may also regulate the segregation of motor and sensory axons during neuromuscular circuit development as well as a role in axonal guidance for synaptic plasticity. EphA4-null mice possess defects in corticospinal tract and anterior commissure. Q40A and E42A mutations lead to 10-fold decreased affinity for EFNB2. EphA4 was initially identified as an ALS modifier in a morpholino-based zebrafish screen (1). EphA4 modulated motor neuron degeneration and disease progression in this ALS model. Those motor neurons that are most vulnerable to degeneration in ALS express higher levels of EphA4, and this kinase appears to inhibit neuromuscular re-innervation by axotomized motor neurons. In humans with ALS, EphA4 expression is inversely linked with disease onset and survival, and loss-of-function mutations in EphA4 are correlated with longer survival. However, decreased signalling of EphA4 also improved functional performance and motor neuron survival in the SOD1G93A mice (2). Very rare loss-of-function variants in the EphA4 gene were also associated with prolonged survival in ALS patients (1). EphA4-specific nanobodies (3) and selective EphA4 agonists were also developed to treat ALS (4) with promising results in delaying the progression of disease in the SOD1G93A mouse model (4). These studies point to EphA4 as a potential target for treatment of ALS, but the precise role of EphA4 in the pathogenesis of ALS is unclear. Interestingly, in CSF samples from ALS patients, while there were no significant changes in the levels of EphA4, there was a significant reduction in the detectable levels of the related Ephrin receptor, EphA1 (5). This description may include information annotated by UniProt and/or Google AI.